Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker CUE
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | Michael Vincent Meluzio VP, Prin. Accounting Officer | CUE Cue Biopharma, Inc. | Sale | 3 | $31.13 | $93.39 Sale | Form 4 ↗ |
| Aug 13, 2026 | Michael Vincent Meluzio VP, Prin. Accounting Officer | CUE Cue Biopharma, Inc. | Sale | 4,106 | $30.35 | $124.6K Sale | Form 4 ↗ |
| Aug 13, 2026 | Michael Vincent Meluzio VP, Prin. Accounting Officer | CUE Cue Biopharma, Inc. | Sale | 1,519 | $29.37 | $44.6K Sale | Form 4 ↗ |
| Aug 13, 2026 | Shao-Lee Lin Chief Executive Officer, Director | CUE Cue Biopharma, Inc. | Sale | 10,460 | $29.48 | $308.4K Sale | Form 4 ↗ |
| Aug 13, 2026 | Shao-Lee Lin Chief Executive Officer, Director | CUE Cue Biopharma, Inc. | Sale | 2,375 | $28.11 | $66.8K Sale | Form 4 ↗ |
| Aug 13, 2026 | Shao-Lee Lin Chief Executive Officer, Director | CUE Cue Biopharma, Inc. | Sale | 5,423 | $27.19 | $147.5K Sale | Form 4 ↗ |
| Aug 13, 2026 | Sumita Ray Chief Legal Compliance Officer | CUE Cue Biopharma, Inc. | Sale | 4 | $31.13 | $125 Sale | Form 4 ↗ |
| Aug 13, 2026 | Sumita Ray Chief Legal Compliance Officer | CUE Cue Biopharma, Inc. | Sale | 6,442 | $30.35 | $195.5K Sale | Form 4 ↗ |
| Aug 13, 2026 | Sumita Ray Chief Legal Compliance Officer | CUE Cue Biopharma, Inc. | Sale | 2,383 | $29.37 | $70.0K Sale | Form 4 ↗ |
| Aug 12, 2026 | Shao-Lee Lin Chief Executive Officer, Director | CUE Cue Biopharma, Inc. | Sale | 5,775 | $27.75 | $160.3K Sale | Form 4 ↗ |
| Aug 12, 2026 | Shao-Lee Lin Chief Executive Officer, Director | CUE Cue Biopharma, Inc. | Sale | 34,225 | $26.99 | $923.7K Sale | Form 4 ↗ |
| Dec 30, 2025 | Pasha Sarraf Director | CUE Cue Biopharma, Inc. | Buy | 77,417 | $0.30 | $23.2K Buy | Form 4 ↗ |
| Dec 30, 2025 | Pasha Sarraf Director | CUE Cue Biopharma, Inc. | Buy | 78,116 | $0.31 | $24.2K Buy | Form 4 ↗ |
| Dec 30, 2025 | Pasha Sarraf Director | CUE Cue Biopharma, Inc. | Buy | 86,947 | $0.32 | $27.8K Buy | Form 4 ↗ |
| Dec 30, 2025 | Pasha Sarraf Director | CUE Cue Biopharma, Inc. | Buy | 77,148 | $0.30 | $23.1K Buy | Form 4 ↗ |
| Dec 30, 2025 | Pasha Sarraf Director | CUE Cue Biopharma, Inc. | Buy | 4,229 | $0.31 | $1,311 Buy | Form 4 ↗ |
| Dec 16, 2024 | Daniel R. Passeri CHIEF EXECUTIVE OFFICER, Director | CUE Cue Biopharma, Inc. | Buy | 30,000 | $1.03 | $30.9K Buy | Form 4 ↗ |
17 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:00 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances